Processa Pharmaceuticals, Inc. (PCSA) Earnings History
Annual and quarterly earnings data from 2010 to 2025
Loading earnings history...
PCSA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PCSA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export PCSA earnings history in CSV or JSON format
Free sign-in required to download data
Processa Pharmaceuticals, Inc. (PCSA) Earnings Overview
As of May 8, 2026, Processa Pharmaceuticals, Inc. (PCSA) reported trailing twelve-month net income of -$14M, reflecting +89.3% year-over-year growth. The company earned $-5.27 per diluted share over the past four quarters.
Looking at the long-term picture, PCSA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$160,000 in fiscal 2010.
Processa Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATHA (-$129M net income), NUVB (-$146M net income, -325.3% margin), CRVS (-$44M net income), PCSA has comparable earnings metrics. Compare PCSA vs ATHA →
PCSA Earnings vs Peers
Earnings metrics vs comparable public companies
PCSA Historical Earnings Data (2010–2025)
16 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | -14.5% | -$14M | $-10.36 | - | - |
| 2024 | -$12M | -6.6% | -$12M | $-96.75 | - | - |
| 2023 | -$11M | +59.4% | -$11M | $-212.00 | - | - |
| 2022 | -$27M | -140.0% | -$28M | $-42.50 | - | - |
| 2021 | -$11M | +40.0% | -$12M | $-373.00 | - | - |
| 2020 | -$19M | -467.0% | -$15M | $-1269.25 | - | - |
| 2019 | -$3M | +10.8% | -$4M | $-304.25 | - | - |
| 2018 | -$4M | -102.8% | -$5M | $-355.00 | - | - |
| 2017 | -$2M | -452.5% | -$2M | $-200.00 | - | - |
| 2016 | $-335,982 | +90.0% | -$2M | $-747.25 | -6719.6% | -38430.4% |
See PCSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCSA — Frequently Asked Questions
Quick answers to the most common questions about buying PCSA stock.
Is PCSA growing earnings?
PCSA EPS is $-5.27, with earnings growth accelerating to +89.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-14M.
What are PCSA's profit margins?
Processa Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are PCSA's earnings?
PCSA earnings data spans 2010-2025. The accelerating earnings trend is +89.3% YoY. Historical data enables comparison across business cycles.